

Bibliografia

- ABDEL-WAHAB, N.; SUAREZ-ALMAZOR, M.E. (2019) - Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. *Rheumatology*, 58, vii40–vii48;
- ARANDA S, JEFFORD M, YATES P, et al (2012). Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial. *Ann Oncol*, Jan 23(1):222-231;
- BENFAREMO D., MANFREDI L., LUCHETTI M.M. et al (2018) - Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. *Curr Drug Saf*. 13(3):150-164;
- BRAHMER JR, LACCHETTI C, SCHNEIDER BJ et al (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology (ASCO) clinical practice guideline. *J Clin Oncol*, 36:1714–68;
- BRITISH GERIATRICS SOCIETY (2017). Fit for Frailty - Consensus best practice guidance for the care of older people living in community and outpatient settings. London, 22p;
- BROENS, TH; HUIS IN'T VELD, RM; VOLLENBROEK-HUTTEN, MM et al (2007). Determinants of successful telemedicine implementations: a literature study. *J Telemed Telecare* 13(6):303-9;
- BUTCHER, HK; BULECHEK, GM; DOCHTERMAN, JMM; et al (2018). *Nursing Interventions Classification (NIC)*. Elsevier Health Sciences, 7ª edição. 512 pg;
- CAPPELLI, LC; GUTIERREZ AK, BINGHAM CO et al (2017). Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. *Arthritis Care Res*, 69:1751_63;
- CHAMPIAT S, LAMBOTTE O, BARREAU E, et al (2016). Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. *Ann Oncol*, Apr 27(4):559–74;
- ELIAS R, MORALES J, PRESLEY C (2017). Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. *Curr Oncol Rep*19:62;
- FABIÃO, A (2004) Pessoa com doença oncológica: Re(encontro com a qualidade de vida – Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto;
- HAANEN JBAG, CARBONNEL F, ROBERT C et al (2017); ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*;28 Suppl 4:iv119–42;
- HENDERSON, V., (2007) *Princípios básicos de enfermagem da CIE*, 1ª ed., Lusodidacta, Portugal, 92p;
- HURRIA A, MOHILE S, GAJRA A et al. (2016). Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. *J Clin Oncol*;34:2366–U104;
- JAMAL S, HUDSON M, FIFI-MAH A et al (2020) Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. *J Rheumatol*, February, 47 (2) 166-175;
- MCILPATRICK S, SULLIVAN K, MCKENNA H et al (2007). Patients' experiences of having chemotherapy in a day hospital setting. *J Adv Nurs* 59(3):264-73;
- MELISSAROPOULOS K., KLAVDIANOU K., FILIPPOPOULOU A. et al (2020) - Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors *Int J Mol Sci*. 21(9): 3389;
- MOORADIAN MJ, NASRALLAH M, GAINOR JF et al (2018) Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. *Semin Arthritis Rheum* 48(6):1127-1132;
- NORONHA V, SEKHAR A, VIJAY M et al. (2020). Systemic therapy for limited stage small cell lung carcinoma. *J Thorac Dis*;12(10):6275-6290;
- PAREDES T., SIMÕES M.R., CANAVARRO M.C. et al (2008) - Impacto da Doença Crónica na Qualidade de Vida: comparação entre indivíduos da população geral e doente com tumor no aparelho locomotor. *Psicologia, Saúde e Doença*, 9 (1), 73-87;
- POSTOW M A, SIDLOW R, HELLMANN MD (2018). Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*, 378:158–68;
- STEVEN N. M.; FISHER B. A (2019) - Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective *Rheumatology* 2019;58:vii29–vii39;
- US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., 2017;
- WANG P, CHEN Y, SONG SY et al. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. *JAMA Oncology*. 2017 Oct 18; 8:730;